Mengel, David

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L., et al. (2020) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 368

Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone

Purro, S. A., Farrow, M. A., Linehan, J., Nazari, T., Thomas, D. X., Chen, Z., Mengel, D., Saito, T., Saido, T., Rudge, P., et al. (2018) · Nature

Alzheimer's disease research and treatmentsPrion Diseases and Protein Misfolding

Cited by 191

Target engagement in an Alzheimer trial: crenezumab lowers amyloid β oligomers in cerebrospinal fluid

Yang, T., Dang, Y., Ostaszewski, B., Mengel, D., Steffen, V., Rabe, C., Bittner, T., Walsh, D. M., & Selkoe, D. J. (2019) · Annals of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 91

NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression

Mengel, D., Mok, T. H., Nihat, A., Liu, W., Rissman, R. A., Galasko, D., Zetterberg, H., Mead, S., Collinge, J., & Walsh, D. M. (2021) · Cells

Prion Diseases and Protein MisfoldingAlzheimer's disease research and treatments

Cited by 12